News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Tokyo Institute of Technology and Astellas Pharma Inc. (YPH.BE) Launch Collaborative Research for New Anti-Dengue Virus Drugs for Neglected Tropical Diseases



3/21/2013 10:45:11 AM

TOKYO--(BUSINESS WIRE)--Tokyo Institute of Technology ("Tokyo Tech"; Tokyo, Japan; President: Yoshinao Mishima) and Astellas Pharma Inc. ("Astellas")(TOKYO:4503)(President and CEO: Yoshihiko Hatanaka) today announced that they have signed a joint research agreement for drug discovery research utilizing Tokyo Tech's TSUBAME2.0 supercomputer to efficiently discover candidates for the treatment of neglected tropical diseases ("NTDs") caused by dengue virus. NTDs, prevalent mainly among the poor in tropical areas of developing countries, are infectious diseases spread by parasites or bacteria. As it is estimated that approximately one billion people are affected with NTDs worldwide, NTDs are a serious healthcare issue that is being addressed on a global scale. Among them, diseases caused by dengue virus, such as dengue fever/dengue hemorrhagic fever are with high unmet medical needs for treatment and development of new therapeutic drugs. There is no existing drug to treat dengue fever/dengue hemorrhagic fever in the market as well as under development, and the effectiveness of some vaccines to prevent dengue virus currently under development is unclear at this time.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES